Biology:Acetylcholinesterase

From HandWiki
Short description: Primary cholinesterase in the body
acetylcholinesterase
File:The reaction catalyzed by acetylcholinesterase.tif
Acetylcholinesterase catalyzes the hydrolysis of acetylcholine to acetate ion and choline
Identifiers
EC number3.1.1.7
CAS number9000-81-1
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example


Acetylcholinesterase (HGNC symbol ACHE; EC 3.1.1.7; systematic name acetylcholine acetylhydrolase), also known as AChE, AChase or acetylhydrolase, is the primary cholinesterase in the body. It is an enzyme that catalyzes the breakdown of acetylcholine and some other choline esters that function as neurotransmitters:

acetylcholine + H2O = choline + acetate

It is found at mainly neuromuscular junctions and in chemical synapses of the cholinergic type, where its activity serves to terminate synaptic transmission. It belongs to the carboxylesterase family of enzymes. It is the primary target of inhibition by organophosphorus compounds such as nerve agents and pesticides.

Enzyme structure and mechanism

AChe mechanism of action[1]

AChE is a hydrolase that hydrolyzes choline esters. It has a very high catalytic activity—each molecule of AChE degrades about 25,000 molecules of acetylcholine (ACh) per second, approaching the limit allowed by diffusion of the substrate.[2][3] The active site of AChE comprises two subsites—the anionic site and the esteratic subsite. The structure and mechanism of action of AChE have been elucidated from the crystal structure of the enzyme.[4][5]

The anionic subsite accommodates the positive quaternary amine of acetylcholine as well as other cationic substrates and inhibitors. The cationic substrates are not bound by a negatively charged amino acid in the anionic site, but by interaction of 14 aromatic residues that line a gorge leading to the active site.[6][7][8] All 14 amino acids in the aromatic gorge are highly conserved across different species.[9] Among the aromatic amino acids, tryptophan 84 is critical and its substitution with alanine results in a 3000-fold decrease in reactivity.[10] The gorge is approximately 20 angstroms deep and five angstroms wide.[11]

The esteratic subsite, where acetylcholine is hydrolyzed to acetate and choline, contains the catalytic triad of three amino acids: serine 203, histidine 447 and glutamate 334. These three amino acids are similar to the triad in other serine proteases except that the glutamate is the third member rather than aspartate. Moreover, the triad is of opposite chirality to that of other proteases.[12] The hydrolysis reaction of the carboxyl ester leads to the formation of an acyl-enzyme and free choline. Then, the acyl-enzyme undergoes nucleophilic attack by a water molecule, assisted by the histidine 440 group, liberating acetic acid and regenerating the free enzyme.[13][14]

Biological function

During neurotransmission, ACh is released from the presynaptic neuron into the synaptic cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic neuron and ACh is synthesized by combining with acetyl-CoA through the action of choline acetyltransferase.[15][16]

A cholinomimetic drug disrupts this process by acting as a cholinergic neurotransmitter that is impervious to acetylcholinesterase's lysing action.

Disease relevance

Main page: Biology:Acetylcholinesterase inhibitor

Drugs or toxins that inhibit AChE lead to persistence of high concentrations of ACh within synapses, leading to increased cholinergic signaling within the central nervous system, autonomic ganglia and neuromuscular junctions.[17]

Mechanism of Inhibitors of AChE

Irreversible inhibitors of AChE may lead to muscular paralysis, convulsions, bronchial constriction, and death by asphyxiation. Organophosphates (OP), esters of phosphoric acid, are a class of irreversible AChE inhibitors.[18] Cleavage of OP by AChE leaves a phosphoryl group in the esteratic site, which is slow to be hydrolyzed (on the order of days) and can become covalently bound. Irreversible AChE inhibitors have been used in insecticides (e.g., malathion) and nerve gases for chemical warfare (e.g., Sarin and VX). Carbamates, esters of N-methyl carbamic acid, are AChE inhibitors that hydrolyze in hours and have been used for medical purposes (e.g., physostigmine for the treatment of glaucoma). Reversible inhibitors occupy the esteratic site for short periods of time (seconds to minutes) and are used to treat of a range of central nervous system diseases. Tetrahydroaminoacridine (THA) and donepezil are FDA-approved to improve cognitive function in Alzheimer's disease. Rivastigmine is also used to treat Alzheimer's and Lewy body dementia, and pyridostigmine bromide is used to treat myasthenia gravis.[19][20][21][22][23][24]

An endogenous inhibitor of AChE in neurons is Mir-132 microRNA, which may limit inflammation in the brain by silencing the expression of this protein and allowing ACh to act in an anti-inflammatory capacity.[25]

It has also been shown that the main active ingredient in cannabis, tetrahydrocannabinol, is a competitive inhibitor of acetylcholinesterase.[26]

Distribution

AChE is found in many types of conducting tissue: nerve and muscle, central and peripheral tissues, motor and sensory fibers, and cholinergic and noncholinergic fibers. The activity of AChE is higher in motor neurons than in sensory neurons.[27][28][29]

Acetylcholinesterase is also found on the red blood cell membranes, where different forms constitute the Yt blood group antigens.[30] Acetylcholinesterase exists in multiple molecular forms, which possess similar catalytic properties, but differ in their oligomeric assembly and mode of attachment to the cell surface.

AChE gene

In mammals, acetylcholinesterase is encoded by a single AChE gene while some invertebrates have multiple acetylcholinesterase genes. Note higher vertebrates also encode a closely related paralog BCHE (butyrylcholinesterase) with 50% amino acid identity to ACHE.[31] Diversity in the transcribed products from the sole mammalian gene arises from alternative mRNA splicing and post-translational associations of catalytic and structural subunits. There are three known forms: T (tail), R (read through), and H (hydrophobic).[32]

AChET

The major form of acetylcholinesterase found in brain, muscle, and other tissues, known as is the hydrophilic species, which forms disulfide-linked oligomers with collagenous, or lipid-containing structural subunits. In the neuromuscular junctions AChE expresses in asymmetric form which associates with ColQ or subunit. In the central nervous system it is associated with PRiMA which stands for Proline Rich Membrane anchor to form symmetric form. In either case, the ColQ or PRiMA anchor serves to maintain the enzyme in the intercellular junction, ColQ for the neuromuscular junction and PRiMA for synapses.

AChEH

The other, alternatively spliced form expressed primarily in the erythroid tissues, differs at the C-terminus, and contains a cleavable hydrophobic peptide with a PI-anchor site. It associates with membranes through the phosphoinositide (PI) moieties added post-translationally.[33]

AChER

The third type has, so far, only been found in Torpedo sp. and mice although it is hypothesized in other species. It is thought to be involved in the stress response and, possibly, inflammation.[34]

Nomenclature

The nomenclatural variations of ACHE and of cholinesterases generally are discussed at Cholinesterase § Types and nomenclature.

Inhibitors

Main page: Biology:Acetylcholinesterase inhibitor

For acetylcholine esterase (AChE), reversible inhibitors are those that do not irreversibly bond to and deactivate AChE.[35] Drugs that reversibly inhibit acetylcholine esterase are being explored as treatments for Alzheimer's disease and myasthenia gravis, among others. Examples include tacrine and donepezil.[36]

Exposure to acetylcholinesterase inhibitors is one of several studied explanations for the chronic cognitive symptoms veterans displayed after returning from the Gulf War. Soldiers were dosed with AChEI pyridostigmine bromide (PB) as protection from nerve agent weapons. Studying acetylcholine levels using microdialysis and HPLC-ECD, researchers at the University of South Carolina School of Medicine determined PB, when combined with a stress element can lead to cognitive responses.[37]

See also

References

  1. "Introduction to Autonomic Pharmacology". Basic and Clinical Pharmacology (8th ed.). McGraw-Hill. 2001. pp. 75–91. ISBN 978-0-07-160405-5. 
  2. "Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states". Chemical Reviews 87 (5): 955–79. 1987. doi:10.1021/cr00081a005. 
  3. "The cholinesterases: from genes to proteins". Annual Review of Pharmacology and Toxicology 34: 281–320. 1994. doi:10.1146/annurev.pa.34.040194.001433. PMID 8042853. 
  4. "Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein". Science 253 (5022): 872–9. August 1991. doi:10.1126/science.1678899. PMID 1678899. Bibcode1991Sci...253..872S. 
  5. "Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs". Chem. Biol. Interact. 87 (1–3): 187–97. June 1993. doi:10.1016/0009-2797(93)90042-W. PMID 8343975. 
  6. "Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants". Biochemistry 31 (40): 9760–7. October 1992. doi:10.1021/bi00155a032. PMID 1356436. 
  7. "Contribution of aromatic moieties of tyrosine 133 and of the anionic subsite tryptophan 86 to catalytic efficiency and allosteric modulation of acetylcholinesterase". J. Biol. Chem. 270 (5): 2082–91. February 1995. doi:10.1074/jbc.270.5.2082. PMID 7836436. 
  8. "The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors". Biochem. J. 335 (1): 95–102. October 1998. doi:10.1042/bj3350095. PMID 9742217.  open access
  9. "Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket". J. Biol. Chem. 268 (23): 17083–95. August 1993. doi:10.1016/S0021-9258(19)85305-X. PMID 8349597.  open access
  10. "Acetylcholinesterase: Mechanism of Catalysis and Inhibition". Current Medicinal Chemistry - Central Nervous System Agents 1 (2): 155–170. 2001. doi:10.2174/1568015013358536. https://www.researchgate.net/publication/233701777.  closed access
  11. "Gorge Motions of Acetylcholinesterase Revealed by Microsecond Molecular Dynamics Simulations". Scientific Reports 7 (1): 3219. 2017. doi:10.1038/s41598-017-03088-y. PMID 28607438. 
  12. "Acetylcholinsterase: A Versatile Enzyme of Nervous System". Annals of Neurosciences 15 (4): 106–111. October 2008. doi:10.5214/ans.0972.7531.2008.150403. 
  13. "Molecular Architecture and Biological Reactions". Chemical & Engineering News 24 (10): 1375–1377. 1946. doi:10.1021/cen-v024n010.p1375. http://sgreports.nlm.nih.gov/ps/access/MMBBRM.pdf. 
  14. Enzyme structure and mechanism. San Francisco: W.H. Freeman. 1985. pp. 14. ISBN 0-7167-1614-3. 
  15. "The Contribution of Drugs and Toxins to Understanding of Cholinergic Function". Trends in Pharmacological Sciences 11 (1): 8–13. 1990. doi:10.1016/0165-6147(90)90034-6. PMID 2408211. http://pubman.mpdl.mpg.de/pubman/item/escidoc:603084/component/escidoc:2355598/603084.pdf. 
  16. Neuroscience (4th ed.). Sinauer Associates. 2008. pp. 121–2. ISBN 978-0-87893-697-7. 
  17. "Acetylcholinesterase and its Inhibitors". Primer on the Autonomic Nervous System. Elsevier. 2012. pp. 631–633. doi:10.1016/b978-0-12-386525-0.00132-3. ISBN 978-0-12-386525-0. 
  18. "National Pesticide Information Center-Diazinon Technical Fact Sheet". http://npic.orst.edu/factsheets/archive/diazinontech.pdf. 
  19. "Clinical Application: Acetylcholine and Alzheimer's Disease". http://web.williams.edu/imput/synapse/pages/IA5.html. 
  20. Anticholinesterase Drugs and Cholinergic Agonists", in Pharmacology and Physiology in Anesthetic Practice. Lippincott-Raven. 1999. ISBN 978-0-7817-5469-9. http://www.anesthesia2000.com/Autonomics/Cholinergics/Cholin2.htm. Retrieved 2012-02-26. 
  21. "5: Autonomic Pharmacology: Cholinergic Drugs". The Pharmacologial Basis of Therapeutics. THe McGraw-Hill Companies. 1996. pp. 161–174. ISBN 978-0-07-146804-6. http://nursingpharmacology.info/Autonomics/Cholinergics/Cholin1.htm. Retrieved 2012-02-26. 
  22. "5: Autonomic Pharmacology: Cholinergic Drugs". Goodman & Gilman's The pharmacological basis of therapeutics. New York: McGraw-Hill. 1996. pp. 1634. ISBN 978-0-07-146804-6. 
  23. Harrison's Principles of Internal Medicine (14 ed.). The McCraw-Hill Companies. 1998. pp. 2469–2472. ISBN 978-0-07-020291-7. https://archive.org/details/harrisonsprincie14harr. 
  24. Autonomic and Somatic Nervous Systems in Netter's Illustrated Pharmacology. Elsevier Health Science. 2004. pp. 43. ISBN 978-1-929007-60-8. 
  25. "MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase". Immunity 31 (6): 965–73. 2009. doi:10.1016/j.immuni.2009.09.019. PMID 20005135. 
  26. "A molecular link between the active component of marijuana and Alzheimer's disease pathology". Mol. Pharm. 3 (6): 773–7. 2006. doi:10.1021/mp060066m. PMID 17140265. 
  27. "Molecular and cellular biology of cholinesterases". Progress in Neurobiology 41 (1): 31–91. July 1993. doi:10.1016/0301-0082(93)90040-Y. PMID 8321908. 
  28. "Histochemical localization of cholinesterase in the amphibian spinal cord and alterations following ventral root section". Journal of Anatomy 94 (Pt 1): 74–81. 1960. PMID 13808985. 
  29. "The histochemical localization of cholinesterases in the central nervous system of the rat". Journal of Comparative Neurology 100 (1): 211–35. 1954. doi:10.1002/cne.901000108. PMID 13130712. 
  30. "Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism". Am. J. Hum. Genet. 52 (5): 928–36. May 1993. PMID 8488842. 
  31. "Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. 2012". Neurochem. Int. 16 (5): 783–797. 2012. doi:10.1016/j.neuint.2012.06.016. PMID 22750491. 
  32. "Old and new questions about cholinesterases". Chem. Biol. Interact. 175 (1–3): 30–44. 2008. doi:10.1016/j.cbi.2008.04.039. PMID 18541228. 
  33. "Entrez Gene: ACHE acetylcholinesterase (Yt blood group)". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=43. 
  34. "Readthrough acetylcholinesterase in inflammation-associated neuropathies". Life Sci. 80 (24–25): 2369–74. 2007. doi:10.1016/j.lfs.2007.02.011. PMID 17379257. 
  35. "Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level". Biochemistry 38 (22): 7032–9. June 1999. doi:10.1021/bi982678l. PMID 10353814. 
  36. A Primer of Drug Action (Eleventh ed.). Worth Publishers. 2007-10-12. pp. 50. ISBN 978-1-4292-0679-2. https://archive.org/details/primerofdrugacti0000juli/page/50. 
  37. "Pyridostigmine bromide and stress interact to impact immune function, cholinergic neurochemistry and behavior in a rat model of Gulf War Illness". Brain, Behavior, and Immunity 80: 384–393. August 2019. doi:10.1016/j.bbi.2019.04.015. PMID 30953774. 
  38. "Inhibitory Effects of Cannabinoids on Acetylcholinesterase and Butyrylcholinesterase Enzyme Activities". Medical Cannabis and Cannabinoids 5 (1): 85–94. 2022-04-19. doi:10.1159/000524086. PMID 35702400. 

Further reading

External links